NASDAQ:NKBP - China Nuokang Bio-Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$5.54
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on research, development, manufacture, marketing and sales of hospital-based medical products. As of December 31, 2010, it sold a portfolio of 15 products, including four principal products: Baquting, its bleeding control product; Kaitong, its lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; Aiduo, its cardiovascular stress imaging agent, and Aiwen, its anti-arrhythmic agent. Its product pipeline includes three product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. In February 2013, it announced the completion of the merger with Kingbird Mergerco. Inc., a wholly owned subsidiary of Kingbird Investment Inc. As a result of the merger the Company became a wholly owned subsidiary of Kingbird Investment Inc.

Receive NKBP News and Ratings via Email

Sign-up to receive the latest news and ratings for NKBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:NKBP
CUSIPN/A
Phone+86-24-24696033

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

China Nuokang Bio-Pharmaceutical (NASDAQ:NKBP) Frequently Asked Questions

What is China Nuokang Bio-Pharmaceutical's stock symbol?

China Nuokang Bio-Pharmaceutical trades on the NASDAQ under the ticker symbol "NKBP."

Has China Nuokang Bio-Pharmaceutical been receiving favorable news coverage?

News stories about NKBP stock have been trending neutral this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. China Nuokang Bio-Pharmaceutical earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future.

How do I buy shares of China Nuokang Bio-Pharmaceutical?

Shares of NKBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is China Nuokang Bio-Pharmaceutical's official website?

The official website for China Nuokang Bio-Pharmaceutical is http://www.nkbp.com/.

How can I contact China Nuokang Bio-Pharmaceutical?

China Nuokang Bio-Pharmaceutical's mailing address is No. 18-1 East Nanping Road Hunnan Natnl New & High-tch Dvlpmnt Zone, SHENYANG, LIA 110171, China. The biopharmaceutical company can be reached via phone at +86-24-24696033.


MarketBeat Community Rating for China Nuokang Bio-Pharmaceutical (NASDAQ NKBP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about China Nuokang Bio-Pharmaceutical and other stocks. Vote "Outperform" if you believe NKBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: Portfolio Manager

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel